At a Glance
- Company: Contraline
- Funding: $92.5 million
- Focus area: Male contraception
- Technology: Long-acting, reversible hydrogel implant
- Next steps: Advance clinical development
What happened?
Contraline has raised $92.5 million in new funding to support development of its male contraceptive technology. The financing will help move its lead programme further through clinical testing.
Why does it matter?
Male contraception options remain limited, with few reversible, long-acting solutions available. A successful product could shift the landscape of reproductive health by expanding contraceptive responsibility and choice.
Who’s behind it?
Contraline is a biotech company focused on developing non-hormonal male birth control. Its approach centres on a hydrogel-based implant designed to block sperm transport without affecting hormone levels.
How was it achieved?
The company’s technology involves injecting a biodegradable hydrogel into the vas deferens to create a physical barrier. The method is designed to be reversible, offering a long-term but non-permanent contraceptive option.
What’s next?
Contraline plans to use the funds to advance clinical trials, generate more safety and efficacy data, and move closer to regulatory approval. Future milestones will likely include expanded trials and potential partnerships.